ISOLATION AND IN VITRO CHARACTERIZATION OF A NOVEL IMMUNOSUPPRESSIVE CYCLOSPORINE METABOLITE
- 1 January 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 47 (1) , 149-155
- https://doi.org/10.1097/00007890-198901000-00033
Abstract
A novel metabolite (M-E) was identified by high-performance liquid chromatography in the serum of cyclosporine-treated renal transplant recipients during a second wave of immunosuppresive activity after disappearance of the initial wave due to the direct effect of CsA. M-E was identified in human serum and porcine bile both by HPLC and by a preparative thin-layer chromatography (TLC). It demonstrated homogeneity with characteristic retention times on C8 and C18 column HPLC systems using a variety of elution systems, and distinctive TLC mobility (Rf 0.35). Metabolite E (M-E) was documented to be a CsA metabolite by radioactive tracer studies, by crossreactivity with a polyclonal sheep antibody in radioimmunoassay, and by the presence of a characteristic mass spectrum. Further, in vitro immunosuppressive assays documented effects of M-E similar to those of CsA. The relative activity of M-E versus CsA was quantitated by potency ratios: for inhibition of normal human mixed lymphocyte culture reactions, the ratio was 0.79 .+-. 0.23. Interindividual differences were observed in patient susceptibility to MLR inhibition not only by CsA, as previously reported by others, but also by M-E. There was a lesser effect of M-E compared with CsA in inhibiting proliferation of, and IL-2 generation by, C3H murine splenocytes stimulated with concanavalin A: the potency ratios for both systems were about 0.5, possibly reflecting an interspecies variability in generation of or susceptibility to M-E. These studies suggest that heretofore unidentified metabolites-including, but not limited to, M-E-may play an important role in the immunosuppressive effect of CsA in man.This publication has 12 references indexed in Scilit:
- IMMUNOSUPPRESSIVE METABOLITES OF CYCLOSPORINE IN THE BLOOD OF RENAL ALLOGRAFT RECIPIENTSTransplantation, 1986
- Inhibition of in Vitro Alloreactivity by Cyclosporin A: Evidence for an Inter‐Individual Variation in SensitivityScandinavian Journal of Immunology, 1986
- COMPARISON OF THE PHARMACOLOGICAL PROFILES OF CYCLOSPORINE, (NVA2)-CYCLOSPORINE AND (VAL2)DIHYDRO-CYCLOSPORINE1985
- Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin AScience, 1984
- Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription.Proceedings of the National Academy of Sciences, 1984
- DISPOSITION OF CYCLOSPORINE IN SEVERAL ANIMAL SPECIES AND MAN .1. STRUCTURAL ELUCIDATION OF ITS METABOLITES1984
- Binding of cyclosporine by human lymphocytes and phospholipid vesicles.The Journal of Immunology, 1983
- IMMUNOLOGICAL AND PHARMACOLOGICAL MONITORING IN THE CLINICAL USE OF CYCLOSPORIN AThe Lancet, 1981
- Macrophage-independent activation of helper T cells. I. Production of Interleukin 2.The Journal of Immunology, 1980
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979